SCHEMBL5226699

SCHEMBL5226699

O=S(=O)(Cl)NN1CCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 5/20 0.43
TSHR P16473 3/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
USP2 O75604 1/20 0.42
CDK4 P11802 1/20 0.42
ALOX15 P16050 1/20 0.42
CCND1 P24385 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
NOTUM Q6P988 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PKM P14618 3/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5263502 0.90 SMN1; SMN2 (0.46) MEN1KMT2AALDH1A1TSHRPOLB
SCHEMBL1852381 0.83 NOTUM (0.45) MEN1KMT2AALDH1A1TSHRPOLB
SCHEMBL5635263 0.80 MAPT (0.51) MEN1KMT2AALDH1A1TSHRPOLB
SCHEMBL10746811 0.80 MEN1 (0.44) MEN1KMT2AALDH1A1TSHRPOLB
SCHEMBL7785220 0.79 ALDH1A1 (0.44) MEN1KMT2AALDH1A1TSHRPOLB
SCHEMBL4156875 0.74 KMT2A (0.63) MEN1KMT2AALDH1A1TSHRPOLB
SCHEMBL6342593 0.72 LIPE (0.47) MEN1KMT2ATSHRL3MBTL1NOTUM
SCHEMBL5698473 0.72 ALDH1A1 (0.48) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL8979214 0.72 ALDH1A1 (0.48) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL1383225 0.71 ALDH1A1 (0.44) MEN1KMT2AALDH1A1TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 MEN1 4183/4885KMT2A 879/4885ALDH1A1 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.